Bonothyrk
Bonothyrk A-21 · Parathyroid Cytomax · A-21 Bioregulator · Бонотирк
Bonothyrk is the Cytomax parathyroid complex - calcium-phosphate axis tissue, not thyroid hormone and not teriparatide (PTH 1-34). People mix up Bonothyrk and Thyreogen because both live in the neck. They are different glands.
Use-case scores
0–10 against the evidence we have, not a gym ranking. Hidden domains do not apply here.
- Longevity / aging3.5/10
Khavinson-school tissue peptide. Single-lab concentration after haircut. Not a Western Phase 3 geroprotector.
Compound card
- Sequence
- Parathyroid glands peptide complex (mixture, not a single CAS)
- Class
- Khavinson Cytomax capsule complex (Parathyroid glands)
- Formula
- Polypeptide extract (Parathyroid gland tissue, <5 kDa)
- Status
- Not FDA-approved · research use
How it works
Bonothyrk (A-21) is a natural Cytomax - a purified polypeptide complex extracted from the parathyroid glands of young calves using Professor Vladimir Khavinson's patented low-temperature filtration method. The resulting short-chain peptides (under 5 kDa) act as tissue-specific epigenetic regulators for the parathyroid chief cells.
**The Parathyroid's Critical Role** Your four parathyroid glands, each roughly the size of a grain of rice tucked behind your thyroid, are among the most physiologically critical structures in the body. Their one job: maintaining blood calcium and phosphate within extremely narrow bounds essential for cardiac function, nerve signaling, muscle contraction, and skeletal integrity.
They do this via Parathyroid Hormone (PTH) - the master calcium regulator. When calcium drops, PTH rises to pull calcium from bone, increase kidney reabsorption, and activate Vitamin D (which then drives intestinal calcium absorption). When calcium is adequate, PTH falls. This feedback loop is extraordinarily precise. When it fails - through aging, vitamin D deficiency, or glandular dysfunction - cascading consequences follow.
**Age-Related Parathyroid Dysfunction** As we age, two problematic patterns emerge: 1. **Secondary hyperparathyroidism** - chronically elevated PTH (often from Vitamin D deficiency) continuously leaches calcium from bone, driving osteoporosis, fracture risk, cardiovascular calcification, and kidney strain. 2. **Hypoparathyroidism** - inadequate PTH from glandular atrophy leads to hypocalcemia, severe muscle cramping, cardiac arrhythmias, and neurological symptoms.
Bonothyrk addresses this by restoring healthy parathyroid chief cell function at the gene expression level - not by providing PTH itself, but by helping the glands produce the right amount autonomously.
**Mechanism of Action** Bonothyrk's peptides penetrate parathyroid chief cell nuclei, binding to chromatin to unwind silenced gene regions and restore the transcriptional programs governing PTH synthesis, calcium-sensing receptor (CaSR) expression, and phosphate homeostasis. This epigenetic restoration is the hallmark of all Khavinson Cytomaxes - it does not override the body's feedback loops but restores the gland's own capacity to self-regulate.
**Skeletal System Integration** Bonothyrk is specifically listed in Khavinson's locomotor apparatus stack (A-4 Sigumir + A-3 Ventfort + A-6 Vladonix + **A-21 Bonothyrk**), recognizing that bone health requires healthy cartilage AND healthy calcium regulation simultaneously. Sigumir rebuilds bone/cartilage tissue; Bonothyrk ensures the PTH-calcium axis that mineralizes that tissue is properly regulated.
Source: PMID: 12677266
Khavinson map
Canonical 41Used in bioregulator stacks
Manufacturer-style organ combinations - not FDA protocols. Every name is a live leaf.
The Khavinson school
Vladimir Khatskelevich Khavinson (1946–2024) spent five decades at what became the St. Petersburg Institute of Bioregulation and Gerontology arguing a simple, stubborn idea: aging is, in part, a failure of tissue-specific peptide signals, and those signals can be restored. The first products were not “peptides” in the Instagram sense. They were Cytamins - polypeptide fractions isolated from a named organ of young animals. Later commercial refinements of those fractions are sold as Cytomaxes (Cytomed / NPCRIZ): still mixtures, still oral capsules, still defined by the source organ rather than a single sequence. When the group identified short active motifs inside those mixtures, they synthesized them as Cytogens - di-, tri-, and tetrapeptides with a one-letter code (KE, AEDG, KED, EDR, KEDP, and so on).
That three-layer stack is the whole map. Cytamin / pharmaceutical extracts (Thymalin, Epithalamin, Cortexin, Retinalamin, Prostatilen) are the clinic-era injectables registered in the former Soviet pharmacopeia. Cytomaxes are the capsule complexes Cytomed still lists as a 21-SKU organ line. Cytogens are the defined synthetics. English-language educators, including Brenden Henry’s public writing at Peptide Science Institute, add a further commercial distinction - later analog SKUs (N-acetyl, amidate, “V2” complexes) sold as more stable or more diverse than the original Cytomed lots. That last layer is a product taxonomy, not a Khavinson paper. We describe it so readers are not gaslit by three bottles with the same organ name. We do not reproduce paid Peptide Mastery protocols, Precision Cell Method language, or anyone else’s course IP.
Full Cytamin → Cytomax → Cytogen map, literature limits, and how we counted 41
The mechanism Khavinson published is epigenetic, not receptor-agonist in the GLP-1 sense. Short peptides are claimed to enter nuclei, interact with DNA/histones, and reopen tissue-specific transcription that condensed with age (heterochromatin → euchromatin). Reviews in the Bulletin of Experimental Biology and Medicine and Neuroendocrinology Letters (PMID 14523363, 15677927, 23888677) are the citable core. Complementary GI pharmacology is not mystical: di- and tripeptides are PEPT1/LAT substrates, which is why oral capsules are even a conversation. What is not established in Western Phase 3 programs is organ-by-organ disease treatment, telomere reversal as a clinical endpoint, or the manufacturer claim that Cytomax is “a third stronger” than Cytogen. Those are NPCRIZ marketing sentences.
Khavinson’s group published hundreds of papers, many in Russian, many in the same journal family. That is a real literature. It is also a literature with limited independent Western replication, small n, and a habit of using one review PMID as a stamp on every organ. On this site a leaf earns its organ story, its Cytomax↔Cytogen pair, its sequence if it has one, and an honest sentence about what has not been shown. Reconstitution math belongs on cytogens sold as vials. Cytomax capsules do not get a fake 5 mg vial.
The 41 we treat as canonical are the 21 Cytomaxes on the public e-peptide/Cytomed list, the 12 Cytogens on that same commercial line (including Vesilut, which Western catalogs often drop), plus eight historically load-bearing molecules that sit beside the capsule SKUs: Epitalon, Vilon, Thymogen, Livagen, Cortagen, Prostamax, Thymalin, and Epithalamin. Honluten, Cortexin, Retinalamin, Prostatilen, Thymulin, N-acetyl-epitalon-amidate, Pinalex, and the GPL Man / GPL Femme kits are covered as adjacent - same school or same storefront, not padded into a fake 41.
Public English-language teaching (including Brenden Henry at peptidescienceinstitute.com) is cited as context, not copied. Paid Peptide Mastery / Peptide Salvation text stays theirs.
History of this molecule
Parathyroid peptide bioregulation is one of the more precise Cytomax ideas: four tiny glands that set calcium, phosphate, and bone turnover via PTH. A tissue complex aimed at parathyroid cells is a bet on those cells’ transcriptional identity, not a bet on injecting PTH.
Teriparatide (Forteo) and abaloparatide are the Western anabolic bone drugs. Bonothyrk is not a 1-34 analog. If a page compares them, compare honestly: one has Fracture Prevention Trial data; the other has Khavinson organ-logic and a capsule SKU.
Thyreogen is thyroid. Bonothyrk is parathyroid. Mixing TSH and PTH on one bottle is how buyers get lost. Calcium, PTH labs, and DEXA still belong to endocrinology.
Caveats
Parathyroid Cytomax is not a US dietary-supplement monograph and not a drug. The tissue-extract model means lot-to-lot composition is a fingerprint, not a single CAS number. English-language “V2” bottles that claim more peptide diversity are a later commercial layer (mass-spec marketing from specific brands) - they are not Khavinson’s 1990s papers. Animal-source capsules are inappropriate if the reader has a religious or allergy constraint on the source species. None of this replaces care for the actual organ disease. Hypercalcemia and hypoparathyroidism are lab diagnoses. A capsule is not cinacalcet and not calcitriol.
Full 41-map: Khavinson bioregulators index · Bioregulator stacks
Research Use Cases
- ✓Parathyroid Health & PTH Regulation: High
- ✓Bone Mineral Density & Osteoporosis Prevention: High
- ✓Muscle Cramping & Neuromuscular Function: Moderate
- ✓Cardiovascular Protection: Moderate
Dosing
| Phase | Dose | Frequency | Notes |
|---|---|---|---|
| Mini-Course / General Preventive (1 box) | 2 capsules (20 mg) | Once daily for 10 days (20 caps total = 1 box) | Per Vita-Stream/Khavinson protocol: standard mini-course. Repeat every 6 months for general skeletal and calcium support. Take 30 minutes before meals. A 60-cap box extends this to a full 30-day course at 2 caps/day. |
| Full Monthly Course (ages 40–50) | 2 capsules (20 mg) | Twice daily for 30 days (120 caps total = 2× 60-cap boxes) | Full 30-day bi-annual course from age 40–45. After 50, consider 3 courses/year. Pairs strongly with Sigumir (A-4) for comprehensive skeletal support. Ensure adequate Vitamin D3 + K2 baseline. Take 30 minutes before meals (morning + evening). |
| Intensive / High-Need Protocol | 2 capsules (20 mg) | Twice daily, repeated monthly as needed | For diagnosed secondary hyperparathyroidism, significant osteoporosis, or post-surgical hypoparathyroidism support. Physician supervision strongly recommended. Combine with Ventfort (A-3) for vascular protection and Vladonix (A-6) for immune support. Maximum: 4 capsules/day (40 mg). |
Administration
Bonothyrk: Not a research vial vs Oral capsule
- No dedicated cytogen on the 12-SKU NPCRIZ poster (none - do not invent a PTH cytogen; Thyreogen is thyroid, different gland). Do not invent one.
- There is no pharmaceutical-extract SKU that is this capsule in a syringe.
- Not teriparatide (PTH 1-34). Not a Thyreogen vial with the name swapped. There is no parathyroid cytogen on the 12-SKU poster.
- Bonothyrk is an oral capsule complex. It is not a 5 mg lyophilized research vial.
- Inventing recon math for a zero-mg Cytomax vial is how people inject the wrong product.
- Not an official Cytomed sublingual tablet, IM ampoule, or eye drop either.
- Official form for Bonothyrk: swallow the capsule with water. No reconstitution step and no 5 mg cake.
- Parathyroid Cytomax (Cytomed A-21): calcium-phosphate axis tissue. Adjacent anatomy to Thyreogen (thyroid), different hormone.
- Course-based (10–30 days, a few times a year in manufacturer folklore), not a daily forever drug.
- Parathyroid Cytomax is a peptide mixture / lot fingerprint, not a single CAS. English “V2” bottles are a later commercial layer, not a Khavinson RCT.
- Russian school literature is not an FDA organ-disease label.
- Third-party lingual SKUs exist in the wild. We do not claim sublingual as the official Cytomed Cytomax form.
Timeline
Who it is for
Parathyroid Health & PTH Regulation
HighPrimary target tissue. Restores age-suppressed parathyroid chief cell function for proper PTH secretion and calcium/phosphate balance.
Bone Mineral Density & Osteoporosis Prevention
HighDysregulated PTH is a primary driver of bone loss. Bonothyrk addresses the hormonal root cause when paired with Sigumir for structural bone support.
Muscle Cramping & Neuromuscular Function
ModerateLow calcium (from parathyroid dysfunction) causes severe muscle cramps and weakness. Bonothyrk supports the calcium regulation that prevents this.
Cardiovascular Protection
ModerateChronic elevated PTH promotes vascular calcification and cardiac hypertrophy. Normalizing PTH is cardioprotective. Pairs well with Ventfort (A-3).
Kidney Health
ModerateExcess PTH increases renal calcium reabsorption stress and kidney stone risk. PTH normalization reduces this burden.
Aging / Longevity Protocol
HighEssential component of the Khavinson locomotor stack. Calcium dysregulation accelerates aging across multiple systems; Bonothyrk addresses this upstream.
Safety & Considerations
Bonothyrk is a natural glandular Cytomax with a 40+ year safety record in Russian clinical practice. It contains no actual PTH hormone and no synthetic analogs. The strict <5 kDa molecular weight filtration removes DNA fragments, prions, and immunogenic material. Important: Because PTH regulation is critical to cardiac and neuromuscular function, individuals with diagnosed parathyroid disorders (hyperparathyroidism, hypoparathyroidism) should use Bonothyrk under physician supervision with regular calcium/PTH blood monitoring. Contraindications per manufacturer: individual intolerance of components, pregnancy, and lactation. Drug interactions: No known direct interactions, but inform your physician if you are on calcium supplements, bisphosphonates, cinacalcet, vitamin D analogs, or cardiac medications - all of which interact with calcium metabolism. Storage: Keep in a dry, dark place between +2°C and +25°C.
Regulatory & Legal Status
Not currently on the WADA 2026 Prohibited List. Policies may change - verify before competition.
Research Chemical
US Compounding: Not eligible / not available
⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.
Limits of current evidence
- Cytomax SKUs are oral capsules. Do not run SubQ reconstitution math on a zero-mg vial.
- Lot-to-lot composition is a fingerprint, not one sequence.
- This site will not treat the named organ disease from a peptide page.
- English-language V2 / analog bottles are a later commercial layer, not a Khavinson RCT.
Verdict
Bonothyrk is a Cytomax capsule complex from Parathyroid glands. It is not the paired cytogen, not a 5 mg research cake, and not a US supplement monograph. The organ story is in the dossier on this page.
Interactions & Contraindications
Bonothyrk is a natural glandular Cytomax with a 40+ year safety record in Russian clinical practice. It contains no actual PTH hormone and no synthetic analogs. The strict <5 kDa molecular weight filtration removes DNA fragments, prions, and immunogenic material. Important: Because PTH regulation is critical to cardiac and neuromuscular function, individuals with diagnosed parathyroid disorders (hyperparathyroidism, hypoparathyroidism) should use Bonothyrk under physician supervision with regular calcium/PTH blood monitoring. Contraindications per manufacturer: individual intolerance of components, pregnancy, and lactation. Drug interactions: No known direct interactions, but inform your physician if you are on calcium supplements, bisphosphonates, cinacalcet, vitamin D analogs, or cardiac medications - all of which interact with calcium metabolism. Storage: Keep in a dry, dark place between +2°C and +25°C.
Frequently Asked Questions
Oral capsule or injection?▼
Bonothyrk vs Thyreogen?▼
Is this teriparatide?▼
Is there a parathyroid cytogen?▼
Capsule reconstitution?▼
What is Bonothyrk A-21 and what does it do?▼
Does Bonothyrk contain parathyroid hormone (PTH)?▼
How does Bonothyrk support bone health?▼
Who might benefit most from Bonothyrk?▼
What peptides pair well with Bonothyrk?▼
Should I monitor blood calcium or PTH levels while taking Bonothyrk?▼
References
- Khavinson VKh et al. “Tissue-specific effects of peptides.” Bulletin of Experimental Biology and Medicine (2005). PMID: 15677927
- Khavinson VKh, Lin’kova NS, Tarnovskaya SI “Short peptides regulate gene expression.” Bulletin of Experimental Biology and Medicine (2013). PMID: 23888677
- Khavinson VKh, Morozov VG “Peptide regulation of aging: from experimental studies to clinical practice.” Advances in Gerontology (2003). PMID: 14523363
- Khavinson VKh “"Peptide bioregulators - a new class of geroprotectors".” Bulletin of Experimental Biology and Medicine (2002). PMID: 12677266
- Khavinson VKh, Anisimov VN “"Peptide regulation of aging".” Rejuvenation Research (2007). PMID: 17516852
- Khavinson VK et al. “"Short peptides: nature, biosynthesis, and properties".” Advances in Gerontology (2019). PMID: 30641757
- Khavinson VK, Morozov VG “"Regulatory peptides and the aging process".” Neuroendocrinology Letters (2003). PMID: 14618157
📚 Related Articles
Looking for a trusted source? See our recommended suppliers
Independently tested · COA-verified · Save 10% with our exclusive code
Verified Sourcing
Note: Using these localized purchase links applies the community discount automatically and supports CalcMyPeptide database maintenance.